The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom from dialysis in adult participants who are at high risk of DGF after undergoing transplant of deceased donor kidney.
AWAKE is a multicenter, prospective study to evaluate the safety and efficacy of ravulizumab in reducing delayed graft function (DGF) in kidney transplant recipients at high risk for DGF. Eligible participants will be randomized in a 1:1 ratio to receive either ravulizumab or placebo intravenously.
Participants will receive ravulizumab via intravenous (IV) infusion.
Participants will receive placebo via intravenous (IV) infusion.
Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
Capital Federal, Argentina
Córdoba, Argentina